-
1 Comment
Ultragenyx Pharmaceutical Inc is currently in a long term downtrend where the price is trading 22.1% below its 200 day moving average.
From a valuation standpoint, the stock is 98.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 25.5.
Ultragenyx Pharmaceutical Inc's total revenue rose by 157.2% to $92M since the same quarter in the previous year.
Its net income has increased by 74.4% to $-24M since the same quarter in the previous year.
Finally, its free cash flow grew by 1.7% to $-82M since the same quarter in the previous year.
Based on the above factors, Ultragenyx Pharmaceutical Inc gets an overall score of 4/5.
ISIN | US90400D1081 |
---|---|
Industry | Biotechnology |
Sector | Healthcare |
CurrencyCode | USD |
Exchange | NASDAQ |
PE Ratio | None |
---|---|
Dividend Yield | 0.0% |
Beta | 0.94 |
Target Price | 91.56 |
Market Cap | 3B |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for RARE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024